5 citations,
January 2017 in “Dermatologic Surgery”
Storing hair follicle micrografts for longer times can cause them to enter a state similar to the natural hair shedding phase, which might impact hair transplant results.
30 citations,
April 2018 in “Experimental Dermatology”
The article concludes that developing in vitro models for human hair structures is important for research and reducing animal testing, but there are challenges like obtaining suitable samples and the models' limitations.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
A user reported losing hair after 7 months of using oral minoxidil, finasteride, and dutasteride, but others reassured that this is likely just a shedding phase where old hairs fall out to make way for new growth. Some users experience sheds every 7-8 months and suggest staying consistent with treatment.
A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.